JORGE E CORTES to Neoplasms
This is a "connection" page, showing publications JORGE E CORTES has written about Neoplasms.
Connection Strength
0.218
-
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 3:S105-12.
Score: 0.045
-
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med. 2007 Jan; 13(1):14; author reply 15-6.
Score: 0.045
-
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer. 2006 Oct 15; 107(8):1918-29.
Score: 0.044
-
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
Score: 0.020
-
Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015 Jul; 26(7):1440-6.
Score: 0.020
-
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013 Nov; 37(11):1472-6.
Score: 0.018
-
Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc. 2006 Sep; 81(9):1241-57.
Score: 0.011
-
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73.
Score: 0.009
-
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920.
Score: 0.004
-
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.
Score: 0.003